<drug type="biotech" created="2016-11-18" updated="2016-11-18">
  <drugbank-id primary="true">DB13151</drugbank-id>
  <name>Anti-inhibitor coagulant complex</name>
  <description>Anti-inhibitor coagulant complex is a freeze-dried sterile human plasma fraction with factor VIII inhibitor bypassing activity to be reconstituted for intravenous administration. Anti-inhibitor coagulant complex contains mainly non-activated factors II, IX, and X and mainly activated factor VII.  It is manufactured from large pools of human plasma.</description>
  <cas-number/>
  <unii>CS849DUN3M</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Antiinhibitor coagulant complex</synonym>
    <synonym language="" coder="">Factor VIII bypassing fraction</synonym>
    <synonym language="" coder="">Factor VIII inhibitor bypassing activity</synonym>
    <synonym language="" coder="">Factor VIII inhibitor bypassing fraction</synonym>
  </synonyms>
  <products>
    <product>
      <name>Feiba NF</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>64193-423</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1986-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA101447</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Feiba NF</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>64193-424</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1986-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA101447</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Feiba NF</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>64193-425</ndc-product-code>
      <dpd-id/>
      <started-marketing-on>1986-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route/>
      <fda-application-number>BLA101447</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Feiba Nf</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02202581</dpd-id>
      <started-marketing-on>1997-10-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid; Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Feiba Nf</name>
      <labeller>Baxalta Canada Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02353903</dpd-id>
      <started-marketing-on>2011-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid; Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Feiba NF</name>
      <ingredients>Anti-inhibitor coagulant complex</ingredients>
    </mixture>
    <mixture>
      <name>Feiba NF</name>
      <ingredients>Anti-inhibitor coagulant complex</ingredients>
    </mixture>
    <mixture>
      <name>Feiba NF</name>
      <ingredients>Anti-inhibitor coagulant complex</ingredients>
    </mixture>
    <mixture>
      <name>Feiba Nf</name>
      <ingredients>Water + Anti-inhibitor coagulant complex</ingredients>
    </mixture>
    <mixture>
      <name>Feiba Nf</name>
      <ingredients>Water + Anti-inhibitor coagulant complex</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Blood Coagulation Factors</category>
      <mesh-id>D001779</mesh-id>
    </category>
    <category>
      <category>Hemostatics</category>
      <mesh-id>D006490</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Kit</form>
      <route/>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid; powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B02BD03">
      <level code="B02BD">Blood coagulation factors</level>
      <level code="B02B">VITAMIN K AND OTHER HEMOSTATICS</level>
      <level code="B02">ANTIHEMORRHAGICS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB13151.pdf?1479504599</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>96</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
